

18th Annual Meeting • March 13-16, 2012

Hilton Americas Houston Hotel • Houston, Texas, USA

• PRELIMINARY PROGRAM •

Monday, March 12, 2012

1:00 p.m.-5:00 p.m.

SRNT Board of Directors Meeting

Tuesday, March 13, 2012

7:00 a.m.-9:00 a.m.

3:00 p.m.-8:30 p.m.

Registration Open

Pre-Conference Workshops

8:30 a.m.-5:00 p.m.

(available at an additional fee)

Pre-Conference Workshop 1

8:30 a.m.-12:00 noon

Dissemination of Treatment Research Findings into Clinical Practice: A Joint SRNT/ATTUD Conference

Presenters: John Hughes, M.D., and Glen Morgan, Ph.D.

A major goal of treatment research is to provide evidence-based treatments to be used in real-world settings. This requires not only efficacy studies but also dissemination and effectiveness studies. The purpose of this workshop is to provide examples of such studies. The workshop is organized by a collaboration between the SRNT Treatment Network and the Association for the Treatment of Tobacco Use and Dependence (www.attud.org). The latter is a professional organization of Tobacco Treatment Specialists (TTSs) that aims to promote evidence-based treatments for tobacco dependence. Monica Sutton, Ph.D. (University of Mississippi), will introduce and Jonathan Foulds, Ph.D. (Penn State University), will moderate the program. John Hughes, M.D. (University of Vermont), will first briefly describe the "evidence-based medicine" approach that ATTUD advocates. Matthew Bars, M.S., CTTS (Fire Department of New York), will describe methods used by FDNY that decreased smoking prevalence from 27% immediately after 9/11 to 7% now. Thomas Payne, Ph.D. (University of

Mississippi), will describe the outcomes of a statewide network of intensive treatment programs. Nancy Rigotti, M.D. (Harvard University), will review proven cessation programs in hospital settings and discuss methods to implement such programs. Christine Sheffer, Ph.D. (University of Arkansas for Medical Sciences) will describe differences in smokers who chose quitline vs. in-person treatments. Christi Patten, Ph.D. (Mayo Clinic), will discuss research on helping significant others prompt smokers to quit and how this might currently be implemented. Matthew Carpenter, Ph.D. (Medical University of South Carolina), will review clinical methods to motivate smokers to make a quit attempt and their applicability across settings. Glenn Morgan, Ph.D. (National Cancer Institute), will make closing remarks.

Pre-Conference Workshop 2

8:30 a.m.-12:00 noon

The Smoking Cessation and Reduction in Pregnancy Treatment (SCRIPT) Program: Translating Science to Prenatal Care Programs and Professional Practices

Presenter: Richard Windsor, Ph.D., M.P.H.

Smoking is one of the most important risk factors for fetal, infant and maternal morbidity and mortality. The "Smoking Cessation and Reduction in Pregnancy Treatment (SCRIPT) Program" was designed to be an integrated component of a patient education program. The "effectiveness" of SCRIPT delivered as part of routine prenatal care by regular providers has been rigorously evaluated (1982–2011). Meta-analyses by the US-DHHS-Agency for Healthcare Research and Quality (AHRQ), the Cochrane Collaboration Review (2007), and multiple evaluation studies in five countries of the acceptability, effectiveness, and cost effectiveness of methods for pregnant smokers have defined The Clinical Practice Guidelines for Treating Tobacco Use and Dependence (AHRQ, 2000 + 2008). Valid and reliable methods exist: (1) to assist patients to quit or significantly reduce smoking; (2) to measure their levels of daily tobacco exposure;

and (3) to evaluate the quality, process, impact, and cost of delivering and adopting SCRIPT procedures for systems of care and practitioners. The purpose of this workshop is to assist participants in: (1) describing current trends and methods to assess tobacco exposure during pregnancy; (2) identifying best practice measurement methods for routine assessment; (3) identifying "Best Practice" counseling methods for pregnant smokers; (4) defining the evidenced-based SCRIPT intervention to assist pregnant smokers to quit smoking; (5) defining process, impact and cost evaluation methods for the SCRIPT intervention; and (6) identifying methods to integrate SCRIPT interventions in OB/prenatal care systems and practices.

Pre-Conference Workshop 3

8:30 a.m.-4:30 p.m.

Cholinergic Regulation of Addiction and Disease: Understanding Mechanisms and Identifying Novel Therapeutic Targets

Workshop Coordinators: Mariella De Biasi, Ph.D., and Darlene Brunzell, Ph.D.

The cholinergic system supports many brain functions including learning and memory, attention, affect, motivation, reward and aversion. The nicotine contained in tobacco effectively hijacks the cholinergic system leading to changes in neural plasticity that support addiction and lead to changes in mood and cognition. These system neuroscience talks will address the diverse classes of nicotinic receptor subtypes that support various behaviors relevant to drug dependence, neurodegenerative disorders and mental illness. Speakers for this full-day workshop include John Dani, Robin Lester, Rory McQuiston, Kelly Dineley, Adriana Alcantara, Christie Fowler, Raad Nashmi and Roger Papke. Ample time is provided for audience discussion in order to stimulate the exchange of scientific ideas for the translation of basic science research. This workshop is intended for individuals who are interested in neurochemical, neuroanatomical, physiological and molecular mechanisms of

SOCIETY FOR RESEARCH ON NICOTINE AND TOBACCO

Hilton Americas Houston Hotel • Houston, Texas, USA

behavior with the goal of identifying novel therapeutic targets for tobacco addiction and related illness.

Pre-Conference Workshop 4

8:30 a.m.-4:30 p.m.

New Methods for Advancing Research on Tobacco Dependence

Tobacco Researchers: Lisa Dierker, Ph.D., Danielle McCarthy, Ph.D., Robin Mermelstein, Ph.D., Tom Piasecki, Ph.D., Megan Piper, Ph.D., and Saul Shiffman, Ph.D.

Quantitative Methods Researchers: Don Hedeker, Ph.D., Stephanie Lanza, Ph.D., Runze Li, Ph.D., and Daniel Rivera, Ph.D.

Discussants: Elizabeth Ginexi, Ph.D., and Linda M. Collins, Ph.D.

The primary goal of this workshop is to increase uptake of new methods for collection and analysis of data from tobacco studies, in order to advance our understanding of complex pre- and post-quit processes, effects of treatment on those processes, and the role of milestones (such as lapse and relapse) in the process of quitting. Speakers will describe challenges and best practices related to studying smoking behavior, in particular smoking cessation, which often involves the collection of intensive longitudinal data or ecological momentary assessment (EMA) data and random assignment to treatment conditions. Open questions in tobacco research that require new methods will be discussed. The time-varying effect model and related methods for addressing new questions using intensive longitudinal data and EMA data will be introduced. To achieve the primary goal, the agenda will include substantive and methodological talks, as well as an invited poster session during which early-career scientists will present their research. The target audience is researchers who have, or plan to collect, intensive longitudinal behavioral data or EMA data related to tobacco dependence. Presenters include renowned tobacco researchers (Lisa Dierker, Ph.D., Wesleyan University; Danielle McCarthy, Ph.D., Rutgers University; Robin Mermelstein, Ph.D., University of Illinois, Chicago; Tom Piasecki, Ph.D., University of Missouri; Megan Piper, Ph.D., University of Wisconsin; Saul Shiffman, Ph.D., University of Pittsburgh) and researchers focused on new quantitative methods (Don Hedeker, Ph.D., University of Illinois, Chicago; Stephanie Lanza, Ph.D., Penn State University; Runze Li,

Ph.D., Penn State University; and Daniel Rivera, Ph.D., Arizona State University). Discussion will be provided by Elizabeth Ginexi, Ph.D., National Cancer Institute, and Linda M. Collins, Ph.D., Penn State University. The workshop is organized by Stephanie Lanza, Ph.D., Research Associate Professor, Penn State University and Scientific Director of The Methodology Center and Megan Piper, Ph.D., Assistant Professor, University of Wisconsin and Lead Researcher, Center for Tobacco Research and Intervention.

Pre-Conference Workshop 5

8:30 a.m.-4:30 p.m.

Biomarker Development for Nicotine Dependence

Chairs: Jed Rose, Ph.D., and Caryn Lerman, Ph.D.

Presenters:

- Pharmacogenomics – George Uhl, M.D., Ph.D., and Sean P. David, M.D., S.M., D.Phil.
- Drug Metabolism – Caryn Lerman, Ph.D., and Rachel Tyndale, M.Sc., Ph.D.
- CNS imaging – Elliott Stein, Ph.D., and F. Joe McClernon, Ph.D.
- Biostatisticians – Chuck Green, Ph.D., and David Conti, Ph.D.

Discussant(s):

- FDA panelist(s): TBD
- Paul Kenny, Ph.D. (discuss preclinical/translational biomarkers potential)

In 2009, 46.6 million adults were regular smokers. Although approximately 70% of smokers wanted to quit, only a modest number of smokers were able to remain abstinent without behavioral therapy, pharmacotherapy, or both. As a result, nearly 440,000 smokers die each year in the U.S. alone. There are three FDA-approved first-line medications for tobacco dependence, yet each has limited efficacy. One of the most significant impediments slowing drug development is the lack of quantitative biomarkers that can more hastily speed or eliminate an experimental pharmacotherapy from further development. If a biomarker could be identified, reliably measured, and consistently analyzed, it could be used to predict quitting success, personalize therapy delivery, and optimize the process of development of new treatment modalities. This symposium will review existing evidence pertaining to pharmacogenomic, drug metabolism, and neuroimaging biomarkers. Drs. Uhl and David will discuss human GWAS data. Drs. Lerman and Tyndale will then discuss human nicotine metabolism,

genotype-metabolism relationships, and how, metabolism markers could be used to tailor a therapeutic strategy for different populations of smokers, and to develop novel treatments. Drs. Stein and McClernon will subsequently discuss functional (MRI) and diffusion tensor imaging (DTI) neuroimaging data that identify neural signatures of activation and functional connectivity that might be used to further stratify smokers for more effective drug development and delivery. Drs. Green and Conti will then present the potential to algorithmically combine these measures into one collective personal risk 'score.' This one-day session will be chaired by Drs. Jed Rose and Caryn Lerman. The incorporation of an FDA-recognized (set of) biomarker(s) for drug development would represent a paradigm shift in how the safety and efficacy of novel medications are ultimately evaluated in early Phase I and II clinical trials, a position where nearly 67% of all clinical drug development fails.

Pre-Conference Workshop 6

1:00 p.m.-4:30 p.m.

Advancing the Science and Practice of Behavioral Support for Smoking Cessation

Presenters: Robert West, Ph.D., and Susan Michie, B.A., M.Phil., D.Phil., CPsychol, AcSS, FEHPsS, FBPsS

Behavioural support can increase success at quitting smoking whether delivered face-to-face individually or in groups, by telephone, text messaging, or internet. The NNT is typically 20-30. Some specific components have been evaluated such as CBT for depression, advice on exercise, use of 'buddy' systems etc. but the key active ingredients are largely unexplored and there is no clear evidence of progression in achieving improved effectiveness. Part of the reason for this is a lack of adequate methodological tools. Several advances in recent years provide opportunities to advance this area of study. These include:

1. The development of systems for specifying the behaviour change techniques (BCTs) used in behavioural support and linking these to underlying theory
2. Improved study designs that permit evaluation of incremental improvements in effectiveness of interventions as a function of components that may be added, deleted or modified
3. Technological developments that allow delivery and rapid innovation of BCTs through a range of modalities, e.g., internet, text messaging

SOCIETY FOR RESEARCH ON NICOTINE AND TOBACCO

18th Annual Meeting • March 13-16, 2012

4. Huge increase in reach of behavioural support through national and regional programmes (e.g., the English Stop-Smoking Services) and new technologies, allowing creation of large datasets
5. Advances in statistical techniques for dealing with n-of-one, within-subject, time series and multi-level designs

This workshop will aim to review the state of the art with regard to methodological opportunities for advancing behavioural support and to begin the process of developing and coordinating a long-term strategy for exploiting these. The ultimate goal will be to achieve a step-change in the effectiveness of behavioural support.

Pre-Conference Workshop 7

1:00 p.m.-4:30 p.m.

Turning Research Into Action

Presenter: Mike Freiberg, J.D.

This workshop will provide a “how to” on drafting effective tobacco control policies, with a focus on three specific tobacco control topics: (1) regulatory gaps related to non-cigarette tobacco products; (2) secondhand smoke infiltration in public housing, common interest communities (condominiums), and other types of multi-unit housing; and (3) drafting effective policies, using as a case study Minnesota’s Tobacco Modernization Act, a law which expanded Minnesota’s tobacco control laws to make them more inclusive of novel tobacco and nicotine products. This workshop will highlight collaborative research between ClearWay MinnesotaSM and the Public Health Law Center, focusing on how the conclusions from these projects can be turned into effective policies. The workshop will provide valuable lessons for researchers, whose research may cause them to see the need for dramatic policy changes. Although these changes may seem obvious to the Principal Investigators of a study, they will not be effectively realized unless they are put into strong policy language that will withstand legal challenges. This workshop will teach participants how to do this. It will be led by the Principal Investigators on ClearWay’s two most recent grants to the Public Health Law Center: Mike Freiberg, J.D., and Warren Ortland, J.D. Mr. Freiberg and Mr. Ortland are both Staff Attorneys with the Public Health Law Center.

5:30 p.m.-7:00 p.m.

Welcome/Awards/Memorial

Langley Award Lectures

Environmental and Behavioral Determinants of Nicotine’s Actions: Questions Left Unanswered
Anthony R. Caggiola, Ph.D.

Variable Nicotine Metabolism: From First to Last Puff

Rachel Tyndale, M.Sc., Ph.D.

7:00 p.m.-8:30 p.m.

Welcome Reception Exhibits Open

Wednesday, March 14, 2012

7:00 a.m.-9:00 a.m.

Network Meeting

Tobacco Related Health Disparities Network

7:15 a.m.-8:15 a.m.

Network Meetings

- *Global Health Network*
- *Basic Science Network*

7:30 a.m.-5:00 p.m.

Registration Open

8:30 a.m.-9:30 a.m.

Keynote Lecture

Ending the Tobacco Epidemic: A Federal Plan

Howard Koh, M.D., M.P.H.

Assistant Secretary for Health, U.S.

Department of Health and Human Services

9:30 a.m.-10:00 a.m.

Refreshment Break

10:00 a.m.-11:15 a.m.

Paper Sessions (concurrent)

Paper Session 1

Varenicline: Learning More About What Works

Paper Session 2

Adolescent Smoking: Beliefs and Building on Technology

Paper Session 3

Dopamine: Everyone’s Favorite Monoamine

Paper Session 4

Biological Indices of Smoke Exposure

Paper Session 5

Tobacco Packs

Paper Session 6

Exploring Nicotine Dependence at the Population Level

11:30 a.m.-1:00 p.m.

Poster Session 1: Pre-Clinical, Public Health, Epidemiology Boxed Lunches

12:00 noon-1:00 p.m.

Breakout Discussions

Small (20-30 people) groups will meet to discuss various transdisciplinary research topics such as understanding genetics, improving training and opportunities for trainees, and translating preclinical findings into clinical applications. Each discussion group will have two moderators and anyone who is interested is invited to participate.

1:00 p.m.-2:30 p.m.

Symposia (concurrent)

Symposium 1

ANHEDONIA IN NICOTINE DEPENDENCE: INTEGRATING PRE-CLINICAL, HUMAN LABORATORY, NATURALISTIC, AND CLINICAL RESEARCH PERSPECTIVES

Adam M. Leventhal, Ph.D.¹, Manoranjan S. D’Souza, M.D., Ph.D.², Janet Audrain-McGovern, Ph.D.³, Jessica Cook, Ph.D.⁴, and John R. Hughes, M.D.⁵

¹University of Southern California;

²University of California San Diego;

³University of Pennsylvania; ⁴University of Wisconsin; ⁵University of Vermont

Symposium 2

NICOTINE EXPOSURE, METABOLISM, AND GENETICS AMONG ALASKA NATIVE PEOPLE

Co-Chairs: Dorothy K. Hatsukami, Ph.D.¹, and Mark Parascandola, Ph.D., M.P.H.²

Presenters: Caroline C. Renner, M.P.H., C.T.T.S.³, Neal L. Benowitz, M.D.^{4,5}, Rachel F. Tyndale, Ph.D., M.Sc.⁶, and Andy Z.X. Zhu⁶
Discussant: Scott J. Leischow, Ph.D.⁷

¹Masonic Cancer Center, University of Minnesota, Minneapolis, MN; ²National Cancer Institute, Tobacco Control Research Branch; ³Clinical Research Services, Alaska Native Tribal Health Consortium, Anchorage, AK; ⁴Division of Clinical Pharmacology, Departments of Medicine and Bioengineering & Therapeutic Sciences; ⁵Helen Diller Comprehensive Cancer Center, University of California, San Francisco; ⁶Departments of Psychiatry, Pharmacology and Toxicology and Centre for Addiction and Mental Health, University of Toronto, Canada; ⁷Arizona Cancer Center, University of Arizona, Tucson, AZ

SOCIETY FOR RESEARCH ON NICOTINE AND TOBACCO

Hilton Americas Houston Hotel • Houston, Texas, USA

Symposium 3

SMOKING CESSATION: INTERPLAY OF GENES AND TREATMENTS

Timothy B. Baker, Ph.D.¹, Andrew W. Bergen, Ph.D.², Laura J. Bierut, M.D.³, Li-Shiun Chen³, Caryn Lerman, Ph.D.⁴, and Marcus R. Munafò, Ph.D., M.Sc.⁵

¹University of Wisconsin School of Medicine; ²SRI International; ³Washington University School of Medicine; ⁴University of Pennsylvania; ⁵University of Bristol

Symposium 4

MINDFULNESS AND SMOKING CESSATION

Chair: David W. Wetter, Ph.D.¹
Presenters: Aimee C. Ruscio², Whitney L. Heppner, Ph.D.¹, Jennifer Irvin Vidrine, Ph.D.¹, and James Davis, M.D.³

Discussant: Jennifer McClure, Ph.D.⁴

¹University of Texas MD Anderson Cancer Center; ²Uniformed Services University; ³University of Wisconsin School of Medicine and Public Health; ⁴Group Health Research Institute

2:30 p.m.-3:00 p.m.

Refreshment Break

3:00 p.m.-4:00 p.m.

Epidemiology and Public Health Theme Lecture

Transforming Tobacco Use into a Minor Public Health Nuisance

Tim McAfee, M.D., M.P.H.

Director, Office on Smoking and Health, National Center for Chronic Disease Prevention and Health Promotion

4:00 p.m.-5:15 p.m.

New Investigator Award Paper Session

Session Chair: Monica Webb Hooper, Ph.D.

4:00 p.m.-4:15 p.m.

ELECTRONIC CIGARETTES DELIVER SIMILAR LEVELS OF NICOTINE AND REDUCE EXPOSURE TO COMBUSTION TOXICANTS AFTER SWITCHING FROM TOBACCO CIGARETTES

Maciej Lukasz Goniewicz, Ph.D., Michal Gawron, M.Sc., Margaret Peng, Peyton Jacob III, Ph.D., and Neal Benowitz, Ph.D.

4:15 p.m.-4:30 p.m.

GALANIN RECEPTOR 1 (GALR1) SNP IS ASSOCIATED WITH CRAVING AND SMOKING RELAPSE

Allison B. Gold, Ph.D.¹, E. Paul Wileyto, Ph.D.¹, Christopher Jepson, Ph.D.¹, Caryn Lerman, Ph.D.¹, Adriana Lori, Ph.D.², and Joseph F. Cubells, Ph.D.²

¹University of Pennsylvania; ²Emory University School of Medicine

4:30 p.m.-4:45 p.m.

SECONDHAND SMOKE EXPOSURE AND SERUM CYTOKINE LEVELS IN CHILDREN

K. Wilson, J. Pier, S. Gates, K. Evans, A. Chhibber, E. Weis, and T. Love

4:45 p.m.-5:15 p.m.

People, Places, and Things: Subjective and Behavioral Reactivity to Proximal and Distal Smoking Cues

Cynthia Conklin, Ph.D.

5:15 p.m.-6:45 p.m.

Poster Session 2: Epidemiology, Public Health, Policy

7:00 p.m.

Screening of the Movie, "Addiction Incorporated"

The explosive story of Victor DeNoble, one of the most important and influential whistleblowers of all time, comes to the big screen in *ADDICTION INCORPORATED*.

In the 1980s, DeNoble was a research scientist at a major tobacco company, where he was tasked with finding a substitute for nicotine that would not cause heart attacks. His quest was to discover if it would be possible to create a cigarette that would be safer for smokers (although not necessarily less addictive). DeNoble succeeded, but in the process produced something that many suspected was true, but the industry had been denying for years: scientific evidence that nicotine was addictive. This set off a chain of events that still reverberates today.

In an act of modern-day heroism, DeNoble took his findings to the people despite being subject to a strict confidentiality agreement, testifying about his research in the infamous 1994 Congressional hearings—the same ones where the seven heads of the major tobacco companies declared that nicotine was not addictive. In the end, an unprecedented alliance of journalists, politicians, attorneys, and whistleblowers banded together to achieve what was once considered impossible: the first ever federal regulation of the tobacco industry.

They all come together to tell their stories in *ADDICTION INCORPORATED*.

Interviews with SRNT members Mitch Zeller, Neal Benowitz, Gregory Connolly, Clifford Douglas, Jack Henningfield, and Matt Myers are part of the movie. Following the movie there will be a discussion that will include the director, Charlie Evans Jr., and Mitch Zeller.

Thursday, March 15, 2012

7:30 a.m.-8:15 a.m.

SRNT Members Meeting (open to all)

8:00 a.m.-5:00 p.m.

Registration Open

8:30 a.m.-9:45 a.m.

Paper Sessions (concurrent)

Paper Session 7

Improving Behavioral Cessation Treatment: Use of Technology and Theory

Paper Session 8

Understanding the Process of Quitting

Paper Session 9

Vaccines, Genes, and Anxiety: Understanding Nicotine Dependence

Paper Session 10

The Biology of Nicotine and Withdrawal

Paper Session 11

Getting the Big Picture: Population-Based Cessation

Paper Session 12

Studying the Impact of Tobacco Control Policies

9:45 a.m.-10:30 a.m.

Refreshment Break

10:30 a.m.-11:30 a.m.

Basic Science Theme Lecture

Properties of Some Interesting Subtypes of Nicotinic Receptors: Expression, Structure, Function, Upregulation, Targets for Smoking Cessation Therapy

Jon Lindstrom, Ph.D.

Trustee Professor of Neuroscience, University of Pennsylvania

SOCIETY FOR RESEARCH ON NICOTINE AND TOBACCO

18th Annual Meeting • March 13-16, 2012

11:30 a.m.-1:00 p.m.

FDA's Center for Tobacco Products: Overview and Research Priorities

Lucinda Miner, Ph.D., Cathy L. Backinger, Ph.D., M.P.H., and Allison C. Hoffman, Ph.D., Food and Drug Administration/Center for Tobacco Products (FDA/CTP)

With the passage of the Family Smoking Prevention and Tobacco Control Act in 2009, FDA was given authority to regulate the manufacture, distribution, and marketing of tobacco products. FDA established the Center for Tobacco Products (CTP) in August 2009 to implement this new regulatory authority to reduce tobacco-related illness and death nationwide. Since its inception, the Center has recognized the importance of strengthening the existing science base to support the regulation of tobacco products. CTP's Office of Science is working to implement a focused research agenda to meet its regulatory science needs and to evaluate population and public health impact. This workshop will provide an overview of the Tobacco Control Act and highlight some of the activities of the CTP, including the new Population Assessment of Tobacco and Health (PATH) study, a national longitudinal, cohort study in collaboration with NIH; graphic health warnings for cigarette packages; and the Tobacco Products Scientific Advisory Committee (TPSAC). Discussion will include information on how FDA communicates with the research community and how the research community can communicate with the FDA. In addition, the presenters will discuss research priorities and funding plans, discuss identified gap areas where more research is needed to help inform tobacco regulation, and the mechanisms that FDA can use to support needed research.

12:00 noon-1:00 p.m.

Breakout Discussions

Small (20-30 people) groups will meet to discuss various transdisciplinary research topics such as understanding genetics, improving training and opportunities for trainees, and translating preclinical findings into clinical applications. Each discussion group will have two moderators and anyone who is interested is invited to participate.

1:00 p.m.-2:30 p.m.

Symposia (concurrent)

Symposium 5

UNDERSTANDING THE ROLE OF METABOLISM IN TOBACCO DEPENDENCE AND CESSATION TREATMENT: FROM ANIMAL, DEVELOPMENTAL AND SPECIAL POPULATION MODELS

Chair: Rachel Tyndale, M.Sc., Ph.D.^{1,2}

Presenters: Sharon Miksys, Ph.D.², Charmaine S. Ferguson², Mark L. Rubinstein, M.D.⁴, Jill M. Williams, M.D.³, and Andy Z.X. Zhu²

Discussant: Neal Benowitz, M.D.⁴

¹CAMH; ²University of Toronto, Ontario, Canada; ³Robert Wood Johnson Medical School, New Brunswick, NJ; ⁴University of California, San Francisco, CA

Symposium 6

SHIFTING THE TOBACCO PARADIGM: CAN THE FDA TOBACCO CONTROL ACT LEAD TO THE END OF COMMERCIAL CIGARETTE SALES IN THE U.S.?

Scott J. Leischow, Ph.D.¹, Mitch Zeller, J.D.², Sue Curry, Ph.D.³, and Tom Glynn, Ph.D.⁴

¹The University of Arizona; ²Pinney and Associates; ³The University of Iowa; ⁴American Cancer Society

Symposium 7

INCREASING OUR UNDERSTANDING OF NONDAILY SMOKING: INDIVIDUAL PATTERNS, SMOKING TRAJECTORIES, AND CULTURAL INFLUENCES

Chairs: Jasjit S. Ahluwalia, M.D., M.P.H., M.S.¹, and Saul Shiffman, Ph.D.^{*2}

Presenters: Carla J. Berg, Ph.D.³, Taneisha S. Buchanan, Ph.D.⁴, Saul Shiffman, Ph.D.², and Hilary A. Tindle, M.D., M.P.H.⁵

Discussant: Neal Benowitz, M.D.⁶

¹Department of Medicine and Center for Health Equity, University of Minnesota;

²Department of Psychology, University of Pittsburgh; ³Department of Behavioral Sciences and Health Education, Emory University School of Public Health;

⁴Department of Medicine and Center for Health Equity; ⁵Department of Medicine, University of Pittsburgh; Division of Clinical Pharmacology, Department of Medicine, University of California San Francisco

Symposium 8

SMOKING CESSATION AND PSYCHIATRIC COMORBIDITY: A BIDIRECTIONAL RELATIONSHIP?

Paul M. Cinciripini, Ph.D.¹, Vance Rabinus, Ph.D.¹, Virmarie Correa-Fernández, Ph.D.¹, Jessica Cook, Ph.D.², and Thomas H. Brandon, Ph.D.³

¹The University of Texas MD Anderson Cancer Center; ²University of Wisconsin School of Medicine and Public Health;

³Moffitt Cancer Center, University of South Florida

2:30 p.m.-3:00 p.m.

Refreshment Break

3:00 p.m.-4:00 p.m.

Policy Theme Lecture

Melanie Wakefield, Ph.D.

Director, Centre for Behavioural Research in Cancer at the Cancer Council Victoria

4:15 p.m.-5:15 p.m.

Clinical Theme Lecture

Back to the Future: Reinvigorating Behavioral Smoking Cessation Research

Thomas Brandon, Ph.D.

Director, Tobacco Research & Intervention Program, H. Lee Moffitt Cancer Center & Research Institute

5:15 p.m.-6:45 p.m.

Poster Session 3: Clinical

6:15 p.m.-7:15 p.m.

Network Meetings

- *Genetics Network*
- *Treatment Network*
- *Public Health Policy Network*

SOCIETY FOR RESEARCH ON NICOTINE AND TOBACCO

Hilton Americas Houston Hotel • Houston, Texas, USA

Friday, March 16, 2012

8:00 a.m.-11:30 a.m.

Registration Open

8:00 a.m.-9:30 a.m.

Symposia (concurrent)

Symposium 9

GENOME-WIDE ASSOCIATION STUDIES ON SMOKING BEHAVIOR AND NICOTINE DEPENDENCE

Chair: Jaakko Kaprio, M.D., Ph.D.¹

Presenters: Sarah Medland, Ph.D.², Pamela Madden, Ph.D.³, and Marcus Munafò, Ph.D., M.Sc.⁴

Discussant: Andrew Bergen, Ph.D.⁵

¹University of Helsinki, Hjelt Institute and Institute for Molecular Medicine, Finland, National Institute for Health and Welfare, Finland; ²Queensland Institute of Medical Research, Australia; ³Washington University School of Medicine, USA; ⁴University of Bristol, School of Experimental Psychology, UK; ⁵SRI International, Molecular Genetics Program, Center for Health Sciences, USA

Symposium 10

RELATIONSHIP BETWEEN TOBACCO AND OTHER SUBSTANCE USE AMONG YOUNG ADULTS, BY RACE ETHNICITY, EDUCATION AND INCOME

Kymberle L. Sterling, Dr.P.H.¹, Jessica M. Rath, Ph.D., M.P.H.², Andrea C. Villanti, Ph.D., M.P.H.^{3,4}, Donna M. Vallone, Ph.D., M.P.H.², and Pebbles Fagan, Ph.D., M.P.H.⁵

¹Institute of Public Health, Georgia State University; ²Department of Research and Evaluation, Legacy; ³The Schroeder Institute for Tobacco Research and Policy Studies, Legacy; ⁴Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Health; ⁵University of Hawaii Cancer Center

Symposium 11

ALCOHOL USE, CRAVING, AND CESSATION OUTCOMES

David Wetter, Ph.D.¹, Michael Businelle, Ph.D.², Cho Lam, Ph.D.¹, Jessica Cook, Ph.D.³, James Davis, M.D.³, and David Drobes, Ph.D.^{*4}

¹University of Texas MD Anderson Cancer Center; ²University of Texas School of Public Health; ³University of Wisconsin School of Medicine and Public Health; ⁴University of South Florida

Symposium 12

TRANSLATING EVIDENCE OF EFFECTIVENESS OF BEHAVIOR CHANGE INTERVENTIONS FOR SMOKING CESSATION INTO A NATIONAL PROGRAM

Robert West, Ph.D.^{1,2}, Andy McEwen, Ph.D., M.Sc.^{1,2}, Fabiana Lorencatto^{1,3}, Leonie Brose¹, Susan Michie^{1,3}, and Suzanne Colby, Ph.D.⁴

¹NHS Centre for Smoking Cessation and Training, UK; ²Health Behaviour Research Centre, University College London, UK; ³Centre for Outcome Research and Effectiveness, University College London, UK; ⁴Center for Alcohol & Addiction Studies, Brown University, Providence, RI, USA

9:30 a.m.-10:00 a.m.

Refreshment Break

10:00 a.m.-11:15 a.m.

Paper Sessions (concurrent)

Paper Session 13

Intermittent Smokers: Who's On and Who's Off?

Paper Session 14

What Happens to Withdrawal When Depression, Aggression, and Anxiety are Also in the Mix?

Paper Session 15

Other Tobacco Products

Paper Session 16

Addressing Secondhand Smoke

Paper Session 17

Alpha Beta Soup: What SNPs Can Tell Us

Paper Session 18

Rapid Response Submissions

11:30 a.m.-1:00 p.m.

Poster Session 4: Rapid Response Submissions

1:00 p.m.

Conference Ends